Benchmark Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $110
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Robert Wasserman maintains a Buy rating on Ligand Pharmaceuticals (NASDAQ:LGND) and raises the price target from $95 to $110.
August 12, 2024 | 4:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Robert Wasserman maintains a Buy rating on Ligand Pharmaceuticals and raises the price target from $95 to $110.
The Buy rating and increased price target from a reputable analyst are likely to positively influence investor sentiment and drive short-term price appreciation for Ligand Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100